Rubicon Research Limited Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 8 Fair Values set on narratives written by author
RUBICON Community Narratives
Future Manufacturing Capacity And Specialty Focus Will Support A Fairly Valued Outlook
Future Manufacturing Capacity And Specialty Focus Will Support A Fairly Valued Outlook
View narrativeTrending Discussion
No trending discussion available.
Recently Updated Narratives
Future Manufacturing Capacity And Specialty Focus Will Support A Fairly Valued Outlook
Snowflake Analysis
Rubicon Research Limited Key Details
- 17.41
- 67.00%
- 14.89%
- 24.1%
About RUBICON
- Founded
- 1999
- Employees
- 1290
- CEO
- Website
View website
Rubicon Research Limited operates as a specialty pharmaceutical company in India, the United States, and internationally. The company develops products in the areas of analgesics/pain management, cardiovascular system, central nervous system, hypokalemia, skeletal muscle relaxants, nicotine replacement therapy, gastrointestinal, metabolic, and immunosuppressant. Its primary proprietary technologies for drug delivery comprising RubiReten, a gastro-retentive system for drugs with poor solubility and a limited window of absorption, as well as RubiSRL for the formulation of sustained release liquids using a combination of ion exchange and membrane diffusion controlled-release technologies. The company was incorporated in 1999 and is headquartered in Mumbai, India.